Epitalon

Epitalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly, distilled from the bovine pineal extract Epithalamin by Vladimir Khavinson's group. The proposed mechanism is epigenetic: short peptides of this kind are argued to enter the nucleus, bind CG-rich promoter sequences and de-repress specific genes, with hTERT the headline target. In cultured human fibroblasts Epitalon induced telomerase activity and allowed cells to divide past the Hayflick limit, and in aged animals and elderly humans it restored the nocturnal melatonin peak and normalised cortisol rhythm. The telomerase story is real in vitro but has never been shown to lengthen telomeres in a living human being, and the DNA-binding model remains a hypothesis rather than a settled mechanism.

Targets: hTERT / telomerase, Pineal melatonin synthesis, CG-rich gene promoters, Interleukin-2 and immune gene expression

• · The two common patterns are 10 mg/day for 10 days or 5 mg/day for 20 days. Courses are repeated one to three times a year, classically in spring and autumn.
• · Used by people who want a gentler introduction. There is no evidence the higher end of the range does anything the lower end does not.

Work out your exact syringe units →

• commonInjection-site redness or a small welt— Usually settles within an hour.
• commonVivid dreams or altered sleep architecture— Consistent with the melatonin-rhythm effect; often reported as pleasant.
• uncommonDaytime drowsiness on the first few days— Tends to resolve as the course continues.
• uncommonMild headache

• Active or recent malignancy — telomerase activation is exactly the wrong direction for a cancer cell, and this is the one theoretical risk worth taking seriously.
• Pregnancy and breastfeeding — no data at all.

• synergythymalin — The classic Khavinson pairing; the two were given together on synchronised courses in the Russian elderly cohorts.
• redundantmelatonin — Both act on the same circadian output; combining them adds little beyond what melatonin already does acutely.

• · No routine bloodwork is established.
• · Sleep tracking across a course is the only signal most users can actually observe.
• · If you have any personal or family cancer history, discuss the telomerase question before starting rather than after.

Not approved as a drug in the US or EU; sold as a research chemical. Registered and used clinically in Russia as part of the peptide bioregulator family.

• Khavinson & Morozov 2003, Neuroendocrinology Letters — long-term follow-up of Epithalamin and Thymalin in elderly patients (trial)
• Khavinson et al., peptide-induced telomerase activation and overcoming of the division limit in human somatic cells (preclinical)
• Anisimov et al., Epithalon and lifespan/tumour incidence in rodent models (preclinical)

The honest structure of the Epitalon mechanism is that there are two claims of very different quality stacked on top of each other. The first is circadian: in aged animals and in elderly human cohorts, Epithalamin and later Epitalon restored the nocturnal melatonin peak and flattened the abnormal cortisol curve that comes with pineal ageing. That is a downstream, observable, physiological effect and it is the one users actually notice. The second claim is epigenetic and much harder. Khavinson's group proposed that short peptides of this size diffuse into the nucleus, sit in the major groove of double-stranded DNA at CG-rich promoter regions, and de-repress transcription the way a very small transcription factor would; the 2005 Neuroendocrinology Letters paper argued the AEDG tetrapeptide makes complementary contacts with specific base sequences. Applied to the hTERT promoter, that model predicts telomerase induction, and in telomerase-negative human fibroblasts Epitalon did induce hTERT mRNA, enzymatic telomerase activity and measurable telomere elongation, and the cells divided past their normal Hayflick ceiling. A 2025 replication in Biogerontology found the same dose-dependent telomere extension, and notably also found alternative-lengthening-of-telomeres activity in cancer lines, which is exactly the direction nobody wants. What has never been shown is any of this happening inside a living human. There is no human telomere-length data on Epitalon at all. So the correct mental model is: melatonin rhythm restoration is plausible and observable; telomerase activation is real in a dish and entirely unproven in a person; and the DNA-binding mechanism that supposedly links them is a hypothesis from one laboratory that has never been independently structurally confirmed.

Four things, in order of how often they actually happen. First, people run it continuously. Every piece of research behind this compound used 10-20 day courses separated by months, and the pulsed structure is not incidental — the model is that you are inducing a change in gene expression that persists after the peptide is gone, not maintaining a blood level. Daily year-round dosing has no basis and no data. Second, people buy the oral capsules and expect the injectable evidence to apply. It does not; nobody has measured how much of an orally dosed anionic tetrapeptide reaches circulation, and the answer is probably not much. Third, people take it for telomeres and then never measure anything, so five years and several thousand dollars later they have no idea whether it did anything. If you are going to run it, at minimum track sleep objectively and check a nocturnal melatonin marker across a course. Fourth, and this is the one with real consequences: people with a personal or family cancer history run it without thinking about the mechanism. Telomerase induction plus demonstrated ALT activation in cancer lines is a genuinely bad combination with an occult malignancy, and 'my forum says it is fine' is not evidence. Get your age-appropriate screening current before your first course, not after your fifth.

• hTERT promoter / CG-rich double-stranded DNA — Not measured. No Kd has been published for AEDG binding to any specific DNA sequence.

  Proposed de-repression of hTERT transcription. In cultured human fibroblasts this produces hTERT mRNA, telomerase enzymatic activity and telomere elongation.

• Pineal melatonin synthesis (indirect) — No receptor identified.

  Restoration of the nocturnal melatonin peak in aged animals and elderly humans. Epitalon is not a melatonin receptor ligand — it acts upstream on pinealocyte function, not on MT1 or MT2.

• Interleukin-2 and immune gene expression — Not characterised.

  Reported normalisation of IL-2 production and lymphocyte subsets in the Russian elderly cohorts, usually in combination with Thymalin.

• TNF and IL-6 in monocyte/macrophage lineage — Not characterised.

  Reduced LPS-stimulated TNF and IL-6 expression in THP-1 cells, which is the cleanest in vitro anti-inflammatory signal for the compound.

• Khavinson & Morozov long-term geroprotection cohort (Epithalamin plus Thymalin in elderly subjects) Open-label controlled clinical study · n=266 · 416 weeks · 2003

  All-cause mortality over 6-8 years of follow-up. Reported 1.6-1.8-fold reduction with Epithalamin, 2.0-2.1-fold with Thymalin, 2.5-fold with the combination, and a 4.1-fold reduction in the subgroup given the combination annually across six years.

Days one to three: often nothing, occasionally noticeably deeper sleep on the first or second evening dose, sometimes daytime grogginess that fades. Days three to seven: this is where most people who respond notice it — vivid dreams, longer time in deep sleep on a wearable, easier sleep onset. Days seven to twenty: the sleep effect either consolidates or it does not; there is no reported second wave. End of course to about four to eight weeks after: users commonly report the sleep change persisting after dosing stops, which is the observation the pulsed protocol is built on, though it has never been formally measured. Six months to years: the longevity claim lives here and is by construction unobservable on any personal timescale. Do not expect to feel anything you can attribute to it.

The canonical pairing is Epitalon plus Thymalin on synchronised courses, and it is the only stack in this class with human outcome data attached — the 4.1-fold mortality figure in the Khavinson cohort came from the combination given annually, not from either compound alone. If you are going to run Epitalon at all, running it with Thymalin is the version that at least matches the protocol that generated the data. Pinealon is often added as the neuronal member of the same family; that is coherent in theory and has no supporting human evidence. Stacking Epitalon with exogenous melatonin is largely pointless: melatonin gives you the acute circadian effect directly and immediately, and Epitalon's entire circadian claim is that it restores your own production. If you want to know whether Epitalon is doing anything to your melatonin rhythm, you need to not be taking melatonin. Epitalon has no known metabolic or CYP interactions, so it stacks harmlessly with essentially anything else on this site from a drug-interaction standpoint.

Against Thymalin: Thymalin has the better human data of the two, moves markers you can actually measure (lymphocyte subsets, infection frequency), and its mechanism does not carry a theoretical cancer hazard. If you are choosing one Khavinson compound to run, Thymalin is the more defensible pick. Against melatonin: melatonin is cheap, oral, extremely well characterised and gives you the circadian effect tonight. Epitalon's proposition is that it restores your own rhythm rather than substituting for it, which if true is better, and which has not been demonstrated in a controlled trial. Against actual telomerase-targeting interventions: there are none available to consumers, which is exactly why Epitalon occupies the space it does. Against TA-65 and similar cycloastragenol products: both rest on in vitro telomerase induction, both lack human telomere outcome data, and Epitalon at least has a mortality cohort behind it, however methodologically weak. Against nothing at all: for the longevity claim specifically, the difference between running Epitalon and running nothing has never been measured in a modern trial, and anyone who tells you otherwise is describing the 2003 Russian cohort as though it were a phase 3.

$30–$120/month. Not verified against current vendor pricing in this session — treat as an order-of-magnitude estimate. A standard course is 100 mg total (10 mg x 10 days) or the same total spread over 20 days, and Epitalon is one of the cheaper research peptides by mass. Because the protocol is one to three courses per year rather than continuous, the honest annualised figure is roughly 60 to 350 USD per year, which makes the per-month framing misleading. Oral bioregulator capsules from Russian brands typically cost more per course than research-grade lyophilised powder.

• ?No human pharmacokinetic data exist for Epitalon by any route — no tmax, no half-life measurement, no bioavailability figure. The 'minutes in plasma' statement is inference from peptide class, not measurement.
• ?Whether orally dosed Epitalon reaches systemic circulation in a meaningful quantity is completely unquantified, and this matters because the oral capsule is the most commonly sold format.
• ?The DNA major-groove binding mechanism has never been confirmed by an independent structural study. No crystal structure or NMR structure of AEDG bound to DNA has been published that I could locate.
• ?No human telomere-length data exist. Not one study has measured leukocyte telomere length before and after an Epitalon course in people.
• ?The Khavinson 2003 mortality cohort was open-label and I could not access the full methods to assess how the control group was constituted or whether randomisation occurred at all.
• ?Whether Epitalon crosses the blood-brain barrier is unknown, which is awkward for a compound whose main claimed effect is on the pineal gland.
• ?The cancer risk is theoretical but the 2025 Biogerontology finding of ALT activation in cancer cell lines makes it less theoretical than it was. Nobody has characterised the actual selectivity margin.
• ?Cost figures here are estimates and were not verified against live vendor pricing.
• ?Whether the 5 mg and 10 mg daily doses differ in effect has never been tested; the two common protocols coexist purely by convention.

• Peptides of pineal gland and thymus prolong human life Khavinson VKh, Morozov VG, Neuroendocrinology Letters, 2003 · PMID 14523363

  The source of the mortality-reduction claim. 266 elderly subjects, 6-8 years of follow-up, open-label. This is the strongest human data the compound has, and it is also unblinded, unreplicated outside Russia, and published in a journal with limited reach.

• Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells Khavinson VKh, Bondarev IE, Butyugov AA, Bulletin of Experimental Biology and Medicine, 2003 · PMID 12937682

  The original in vitro telomerase result in telomerase-negative human fibroblasts. Everything the internet says about Epitalon and telomeres traces back here.

• Peptide promotes overcoming of the division limit in human somatic cell Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD, Bulletin of Experimental Biology and Medicine, 2004 · PMID 15455129

  The Hayflick-limit result — fibroblasts continuing to divide past their normal ceiling after Epitalon exposure.

• Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity Al-Dulaimi S, Thomas R, Matta S, Roberts T, Biogerontology, 2025 · PMID 40908429

  An independent 2025 replication of the telomere-lengthening effect outside the Khavinson group, which materially strengthens the in vitro claim. It also found alternative-lengthening-of-telomeres activation in cancer cell lines, which is the strongest published support for the malignancy caution.

• DNA double-helix binds regulatory peptides similarly to transcription factors Khavinson VKh, Solovyov AY, Zhilinskiy DV, et al., Neuroendocrinology Letters, 2005 · PMID 15990728

  The theoretical basis for the whole bioregulator model — that AEDG and its relatives bind the DNA major groove complementarily. Read it as a hypothesis paper, not as settled structural biology.

• Overview of Epitalon — highly bioactive pineal tetrapeptide with promising properties Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L, International Journal of Molecular Sciences, 2025 · PMID 40141333

  The most current review, and the fastest way to see the whole evidence base in one place including the melatonin-synthesis link.

• Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides Ashapkin V, Khavinson V, Shilovsky G, Linkova N, Vanyushin B, Molecular Biology Reports, 2020 · PMID 32399807

  Shows TERT expression modulation by short peptides in mesenchymal stem cells, and usefully shows the effect differs between replicative and stationary ageing models — the effect is not universal.

• Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line Avolio F, Martinotti S, Khavinson VK, et al., International Journal of Molecular Sciences, 2022 · PMID 35408963

  Independent-lab in vitro anti-inflammatory data on Epitalon and four sibling peptides — reduced TNF and IL-6 after LPS stimulation.